Research paperTight-binding inhibitors—IV. Inhibition of adenosine deaminases by various inhibitors☆
References (19)
Biochem. Pharmac.
(1975)- et al.
Biochem. Pharmac.
(1975) Biochem. Pharmac.
(1976)- et al.
Biochem. Pharmac.
(1975) - et al.
J. Am. chem. Soc.
(1970) - et al.
J. med. Chem.
(1974) - et al.
J. heterocyclic Chem.
(1974) - H. W. Dion, P. W. K. Woo and A. Ryder, Ann. N.Y. Acad. Sci., in...
- et al.
There are more references available in the full text version of this article.
Cited by (365)
Kinetics of Drug-Target Binding: A Guide for Drug Discovery
2022, Comprehensive PharmacologyZinc enzymes in medicinal chemistry
2021, European Journal of Medicinal ChemistryCitation Excerpt :Overall, ADA, either in humans or in Plasmodium, is an important therapeutic target, and many potent ADA inhibitors have been reported to date. Coformycin (123, Ki = 10 pM, see Fig. 23) and pentostatin (124, Ki = 2.5 pM, 2'deoxycoformycin), two natural products with very strong potency against ADA, could be viewed as the mimics of the transition state and intermediate in the ADA-adenosine catalyzed reaction [88,97]. Pentostatin has effects on multiple lymphoproliferative malignancies, particularly hairy cell leukemia [98] and was approved by U.S. FDA in 1991 to treat hairy cell leukemia in adult patients.
Structure activity relationship, 6-modified purine riboside analogues to activate hSTING, stimulator of interferon genes
2020, Bioorganic and Medicinal Chemistry Letters
- ☆
This work was supported by USPHS Grant CA 07340.
- †
T. Spector is from the Wellcome Research Laboratories, Research Triangle Park, NC.
Copyright © 1977 Published by Elsevier Inc.